

# Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma.

**Running title: Muscle wasting during NACRT for LARC**

S. Levolger, MD<sup>1</sup>, M.G. van Vledder, MD, PhD<sup>1</sup>, W.J. Alberda, MD<sup>2</sup>, C. Verhoef, MD, PhD<sup>2</sup>, R.W.F. de  
Bruin, PhD<sup>1</sup>, J.N.M. IJzermans, MD, PhD<sup>1</sup>, J.W. Burger, MD, PhD<sup>2</sup>

Department of Surgery, Erasmus MC – University Medical Center, Rotterdam, The Netherlands

Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

## **Corresponding author:**

S. Levolger

Department of Surgery

Erasmus MC – University Medical Center

Wytemaweg 80

3015 CE Rotterdam, The Netherlands

T +31 10 704 36 83

E [s.levolger@erasmusmc.nl](mailto:s.levolger@erasmusmc.nl)

**Keywords** Muscle Wasting, Sarcopenia, NACRT, Rectal Carcinoma, Disease-Free Survival, Overall Survival

## Abstract

**Background & Aims** Neoadjuvant chemoradiotherapy (NACRT) has increased local control in locally advanced rectal cancer. Reduced skeletal muscle mass (sarcopenia), or ongoing muscle wasting, is associated with decreased survival in cancer. This study aims to assess the change in body composition during NACRT and its impact on outcome using computed tomography (CT) imaging in locally advanced rectal cancer (LARC) patients.

**Methods** LARC patients treated with NACRT were selected from a prospectively maintained database and retrospectively analyzed. One-hundred twenty-two patients who received treatment between 2004 and 2012 with available diagnostic CT imaging obtained before and after NACRT were identified. Cross-sectional areas for skeletal muscle was determined, and subsequently normalized for patient height. Differences between skeletal muscle areas before and after NACRT were computed, and their influence on overall and disease-free survival was assessed.

**Results** A wide distribution in change of body composition was observed. Loss of skeletal muscle mass during chemoradiotherapy was independently associated with disease-free survival (HR0.971; 95% CI:0.946 – 0.996; p =0.025) and distant metastasis-free survival (HR0.942; 95% CI:0.898 – 0.988; p =0.013). No relation was observed with overall survival in the current cohort.

**Conclusions** Loss of skeletal muscle mass during NACRT in rectal cancer patients is an independent prognostic factor for disease-free survival and distant metastasis-free survival following curative intent resection.

## Introduction

Colorectal cancer is the third most common malignancy among male and second most common malignancy among female patients worldwide. [1] It is a leading cause of cancer death in more developed countries. Rectal cancer accounts for up to 30% of all colorectal malignancies. For patients with locally advanced rectal cancer, neoadjuvant chemoradiotherapy (NACRT) combined with total mesorectal excision (TME) is considered best available treatment. [2, 3]

Recently, sarcopenia (muscle wasting) has been described as a potent prognostic marker in gastrointestinal and hepatopancreatobiliary malignancies. [4-15] Sarcopenic patients, i.e. patients with a lesser quantity of muscle mass, have an increased risk for early death. Age, cancer cachexia and oncological treatment may contribute to this state of low muscle mass. [16-18] Interestingly, NACRT itself has been reported to reduce skeletal muscle mass in esophagogastric cancer patients. [16] Another study confirmed these findings, and furthermore showed that greater loss of muscle mass during neoadjuvant treatment is associated with an increased risk of postoperative mortality. [19] Likewise, in non-resectable colorectal cancer patients, skeletal muscle loss after systemic chemotherapy is an independent, negative prognostic factor. [20] Interventions to stop or even reverse progressive muscle wasting in patients undergoing potentially curative anti-cancer therapy are currently being investigated and would, if found, provide new strategies in the management of cancer patients.

To this moment, the impact of NACRT on body composition in patients with locally advanced rectal cancer (LARC) has not yet been described. Therefore, in the current study we aim to (1) investigate whether NACRT induces a change in body composition in LARC patients, (2) assess the impact of change in body composition during NACRT on outcome (i.e. short-term outcome, overall survival, disease-free survival, and development of distant metastases).

# Methods

## Patients

All histologically confirmed, LARC patients who underwent NACRT and TME in the Erasmus MC Cancer Institute, a tertiary referral center in the Netherlands for locally advanced and stage IV colorectal cancer, between August 2004 and December 2012 289 patients were enrolled in a prospectively maintained database and retrospectively analyzed. The study protocol was approved by medical ethical committee of the Erasmus MC, University Medical Center, Rotterdam, The Netherlands (MEC-2017-239). LARC was defined as T3 or T4 rectal tumors (i.e. tumors located  $\leq 15$  cm of the anal verge as determined by MRI and colonoscopy) with clinical suspicion of narrow or involved circumferential resection margins (CRM) with or without potentially malignant lymph nodes, or rectal tumors with potentially malignant lymph nodes outside the TME plane, as previously described. [21] Collected data included details on patient age, gender, body-mass index (BMI), comorbidities, cancer stage, carcinoembryonic antigen (CEA), surgical and chemoradiotherapeutic treatment, clinical response rate, recurrence and survival. From the initial 289 patients, 122 patients received abdominal computed tomography (CT) imaging before standardized preoperative chemoradiotherapy (preCRT), and a restaging CT scan (postCRT) to identify any possible previously non-detectable distant metastases, according to local protocol. [22] Only patients with adequate preCRT and postCRT scans were considered eligible for inclusion in the current study.

## Preoperative chemoradiotherapy and surgical resection

All patients received preoperative chemoradiation therapy as a long course (50 Gy) delivered in 25 fractions in accordance to the Dutch guidelines, i.e. chemoradiotherapy for rectal cancer classified as

LARC. Capecitabine (825 mg/m<sup>2</sup>) was administered orally twice a day during radiotherapy days, and radiotherapy was administered via a three-field technique, using one posterior and two lateral portals, a four-field box or with five fields using intensity modulated radiotherapy. [23]

TME was performed after completing chemoradiation, if considered eligible for resection. A midline laparotomy was carried out in all patients. A primary anastomosis was performed whenever possible. A diverting ileostomy was created at the discretion of the treating physician. In T4 tumors involving the sphincter apparatus after NACRT, an abdominoperineal resection was performed. In T4 tumors involving adjacent structures after NACRT (e.g. prostate, uterus, bladder) these were resected simultaneously. Intraoperative radiotherapy was applied if the circumferential resection margin (CRM,  $\leq 2$  mm) was considered to be at risk. [24]

### **Postoperative follow-up**

Patients follow up was done on an outpatient basis by periodic six months CT imaging or abdominal ultrasonography during the first two postoperative years, followed by yearly imaging for the remainder of the follow-up. Serum CEA determination was done at intervals of three to six months during the first three years of follow-up, and subsequently every six months during the final years of follow-up. Patients were followed up for at least 5 years in case of no recurrence. None of the patients were treated with adjuvant chemotherapy according to the Dutch guidelines. The national civil registry was consulted for definitive survival data.

### **Assessment of body composition**

Body composition was measured on standard diagnostic CT scans with FatSeg version 4.0 (Erasmus MC – BIGR, Rotterdam, Netherlands). Cross-sectional areas (cm<sup>2</sup>) of skeletal muscle mass was measured at the level of the third lumbar vertebrae as previously described. [15]

### **Statistical analysis**

Continuous data are presented as mean  $\pm$  SD or median (IQR) as appropriate. Categorical data are presented as number counts and percentages. The Student's *t*-test was used for assessment of differences between groups for continuous variables. The  $\chi^2$  or Fisher's exact test was used for assessment of differences between groups for categorical variables where appropriate. Skeletal muscle mass was normalized for patient height (skeletal muscle index [SMI]). Paired *t*-test was used for the between group comparisons of continuous variables for SMI on preCRT and postCRT scans. Relative change in cross-sectional areas ( $\Delta$  CSA = postCRT / preCRT) were computed for SMI. Gender specific tertiles were determined for  $\Delta$  SMI. Overall and disease-free survival rates were calculated using the non-parametric Kaplan–Meier method and subsequently compared with the log rank test. Univariate and multi-variable Cox regression analyses were performed to investigate the association between  $\Delta$  SMI and survival. Hazard Ratios (HR) with 95% confidence intervals (95% CI) were computed.

Furthermore, age, gender, diabetes, BMI, tumor location, CEA, surgical procedure, intraoperative radiotherapy, pathologic T-, N- and M- stage, circumferential resection margin, and pathologic complete response were included in the univariate Cox regression analysis. These variables were checked for interaction and confounding. They were subsequently included in the multivariable model if a p-value < 0.05 was found in univariate analysis.

All statistical analyses were performed using SPSS version 21.0 (SPSS, Chicago, Illinois, USA). A p-value < 0.05 was considered statistically significant.

# Results

## Clinical characteristics and body composition

One hundred and twenty-two patients, with a median follow-up of 41 months (IQR 26 – 62) were eligible for inclusion (Table 1). During the follow-up period, 50 (41.0%) patients developed recurrent or metastatic disease, and 35 patients (28.7%) died. Forty (32.8%) patients had metastatic disease at onset of NACRT. Twenty-nine (23.8%) patients were treated by liver first approach. [25, 26] Eleven patients underwent synchronous resection. In the studied population, median length of hospital stay was 8 (IQR: 7 – 11) days.

Abdominal CT-imaging was obtained at median 48 (IQR: 35 – 65) days prior to onset of NACRT.

Restaging scans were obtained at a 28 (IQR: 21.5 – 39.5) days after completion of NACRT. Following NACRT, mean skeletal muscle index (SMI) remained unchanged. Despite minimal changes in the mean SMI, a wide distribution in change of body composition was observed.

## Loss of muscle mass and disease stage

After NACRT, lower SMI was found in patients with cT4 tumours when compared to patients with cT3 tumours ( $48.1 \pm 8.3$  versus  $44.7 \pm 8.2$ ,  $p = 0.024$ ). No association between clinical disease stage and  $\Delta$  SMI was observed.

For analytical purposes, gender-specific tertiles for  $\Delta$  SMI were created ( $< -1.95\%$ ;  $-1.95\% - 1.84\%$ ;  $> 1.84\%$  for male patients and  $< -4.53\%$ ;  $-4.53\% - 1.90\%$ ;  $> 1.90\%$  for female patients). Comparing patients in the obtained tertiles for  $\Delta$  SMI, no differences in patient demographic and clinical characteristics (i.e. age, gender, BMI, clinical TNM staging, CEA, tumor height, surgical procedure, and

IORT), pathologic TNM staging, pathologic CRM, and pathologic complete response were observed. There was a weak negative relationship between pre-NACRT SMI and  $\Delta$  SMI (Pearson's  $r$ : -0.254;  $p$  = 0.005), i.e. patients with a higher quantity of muscle mass prior to NACRT experienced greater loss of muscle mass. Vaso-invasion was present in 10 (31.2%) patients in the lower tertile, 3 (8.8%) in the middle tertile, and in 3 (9.4%) patients in the upper tertile for  $\Delta$  SMI respectively ( $p$  = 0.021).

### **Overall survival**

The one-, three-, and five-year overall survival (OS) rates in the current cohort were 93%, 77%, and 69% respectively. A median survival time was not reached. Patients in the lower tertile for  $\Delta$  SMI had one-, three-, and five-year OS rates of 95%, 68%, and 68% respectively; patients in the middle tertile for  $\Delta$  SMI had one-, three-, and five-year OS rates of 95%, 82%, and 65%; and patients in the higher tertile for  $\Delta$  SMI had one-, three-, and five-year OS rates of 90%, 80%, and 74% (Figure 1, log-rank  $p$  = 0.520).

Additionally, gender-specific cut-off values for sarcopenia as previously reported in literature were investigated for their impact on overall survival. [17] No association could be found between sarcopenia pre-operatively (i.e. using the post-NACRT CT scan) and OS (HR: 1.313; 95% CI: 0.675 – 2.551;  $p$  = 0.422) or sarcopenia pre-NACRT and OS (HR 1.183; 95% CI: 0.607 – 2.305;  $p$  = 0.621).

### **Disease-free survival**

The one-, two-, and three- -year disease-free survival (DFS) rates were 72%, 62%, and 57% respectively. Eight (6.6%) patients developed local recurrence, and 46 (37.7%) patients developed distant metastases. A median DFS time was not reached. An association was observed between  $\Delta$  SMI and DFS in log-rank analysis (Figure 2) and in multivariable analysis (HR 0.971; 95% CI: 0.946 – 0.996;  $p$  = 0.025). Moreover,



analysis of patients without evidence of metastatic disease at presentation revealed that  $\Delta$  SMI was an independent predictor for the development of distant metastases following curative intent treatment in multivariable Cox-regression analysis (HR 0.942; 95% CI: 0.898 – 0.988;  $p = 0.013$ ) (Table 3). The one-, three-, and five-year DMFS rates were 74%, 51%, and 51% respectively for patients in the lowest tertile for  $\Delta$  SMI, compared with 77%, 73%, and 73% respectively for patients in the middle tertile for  $\Delta$  SMI, and 100%, 92%, and 85% respectively for patients in the upper tertile for  $\Delta$  SMI (Figure 3).

There was no association between pre-operative sarcopenia and DFS using pre-defined cut-off values (HR: 1.153; 95% CI: 0.662 – 2.009;  $p = 0.615$ ). Likewise, there was no association between pre-NACRT sarcopenia and DFS (HR 0.910; 95% CI: 0.521 – 1.592;  $p = 0.742$ ).

## Discussion

This study describes the change in body composition which may be observed in patients undergoing NACRT for locally advanced rectal cancer. This is the first study to show that loss of muscle mass during NACRT, assessed by use of routinely obtained diagnostic CT images, has a strong association with disease-free survival and distant metastasis-free survival. This technique is inexpensive, readily available, and may thus help identify patients at risk for detrimental outcome. The results of this study may be used to determine inclusion criteria for future clinical studies investigating treatment regimens aimed at stopping or reversing muscle loss in cancer patients, as well as for future clinical studies investigating follow-up regimens following curative intent rectal cancer surgery.

A wide variation was observed in the amount of muscle loss during NACRT. As such, tumor biology rather than NACRT per se is more likely to be the causative factor inducing this catabolic state. Opposed to what we expected, we did not observe any association between disease-stage and the amount of muscle loss during NACRT. However, we did observe an association between vascular invasion and muscle loss during NACRT. Colorectal cancer is known to be associated with different molecular subtypes, with no association to TNM staging. [27] Select molecular subtypes may be associated with a more aggressive tumor biology and stronger systemic catabolic response. A study investigating the association between colorectal cancer genotyping and muscle wasting is currently being undertaken by our research group.

Skeletal muscle loss during NACRT was associated with poor disease-free survival, and a higher risk of developing distant metastasis during follow-up in the current population. These findings are in line with prior literature on esophageal cancer and non-resectable colorectal cancer patients. [19, 20] Another study showed that loss of muscle mass during NACRT is associated with increased postoperative mortality following surgical resection for esophageal cancer. [19] Yet another study reported non-

resectable colorectal cancer patients receiving systemic therapy to have a reduction in both progression-free survival and overall survival if skeletal muscle loss was observed during treatment. [20] While loss of muscle mass during NACRT was strongly associated with DFS and DMFS, single time point measurements for sarcopenia that are widely used were not predictive of survival in the current population.

Despite mounting evidence for sarcopenia and muscle wasting to be associated with poor survival and decreased quality of life [28, 29], it is still unknown whether targeted treatment of muscle wasting may improve outcome. Over the past decade our understanding of muscle wasting in cancer has greatly increased [30, 31], and has led to the initiation of clinical trials investigating interventional strategies aimed at halting or reversing cancer related muscle wasting. [32-35] Whether these treatment regimens are efficacious remains to be answered, but if so the interval between chemoradiotherapy and surgery might offer a perfect window of opportunity to improve the overall condition of LARC patients.

There are several limitations to this present study, some of which have already been described. Information regarding change of bodyweight was not gathered routinely in this cohort. Furthermore, information regarding possible lack of appetite, anorexia, was not available on a consistent basis. Likewise, no information regarding physical status and performance was available for these patients. Lastly, although suggestively differences in tumor biology may explain the findings reported within this study, validating this hypothesis was not within the scope of the current study. Data regarding vaso-invasion, perineural growth, and lymphoinvasion was missing for a considerable number of patients. Due to consequential loss of power we did not include these prognostic factors in our multivariable analyses.

## Conclusions

This study found loss of skeletal muscle mass during, but not necessarily attributable to, neoadjuvant chemoradiotherapy in resectable rectal cancer patients to be a novel independent prognostic factor for disease-free survival and distant metastasis-free survival following total mesorectal excision. This knowledge may benefit in patient expectation management following curative intent treatment, as well as provide grounds for future clinical studies investigating whether there may be a role for adjuvant therapy in patients showing greatest loss of muscle mass, i.e. who were found to have the highest rate of metastasis development.

**Funding** No funding from external organizations was obtained.

**Conflict of interest** All authors declare they have no conflict of interest.

**Acknowledgements** We would like to thank prof.dr. W.J. Niessen and M. Koek, MSc from the Biomedical Imaging Group Rotterdam (BIGR), department of bioinformatics and radiology, Erasmus MC, Rotterdam, the Netherlands for providing FatSeg version 4.0.

## References

- [1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin.* 2015;65:87-108.
- [2] Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med.* 2001;345:638-46.
- [3] Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med.* 2006;355:1114-23.
- [4] Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. *Br J Surg.* 2013;100:1523-30.
- [5] Itoh S, Shirabe K, Matsumoto Y, Yoshiya S, Muto J, Harimoto N, et al. Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. *Ann Surg Oncol.* 2014;21:3063-8.
- [6] Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. *Supportive Care Cancer.* 2014.
- [7] Peng P, Hyder O, Firoozmand A, Kneuert P, Schulick RD, Huang D, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. *J Gastrointest Surg.* 2012;16:1478-86.
- [8] Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, et al. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. *Ann Surg.* 2014.
- [9] Peng PD, Van Vledder MG, Tsai S, De Jong MC, Makary M, Ng J, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. *HPB.* 2011;13:439-46.
- [10] van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. *Br J Surg.* 2012;99:550-7.
- [11] Reisinger KW, van Vugt JLA, Tegels JJW, Snijders C, Hulsewe KWE, Hoofwijk AGM, et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. *Ann Surg.* 2014.
- [12] Sheetz KH, Zhao L, Holcombe SA, Wang SC, Reddy RM, Lin J, et al. Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer. *Dis Esophagus.* 2013;26:716-22.
- [13] Sabel MS, Terjimanian M, Conlon ASC, Griffith KA, Morris AM, Mulholland MW, et al. Analytic morphometric assessment of patients undergoing colectomy for colon cancer. *J Surg Oncol.* 2013;108:169-75.
- [14] Liefvers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. *Br J Cancer.* 2012;107:931-6.
- [15] Levolger S, van Vledder MG, Muslem R, Koek M, Niessen WJ, de Man RA, et al. Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinoma. *J Surg Oncol.* 2015.
- [16] Awad S, Tan BH, Cui H, Bhalla A, Fearon KC, Parsons SL, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. *Clin Nutr.* 2012;31:74-7.
- [17] Prado CM, Liefvers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. *Lancet Oncol.* 2008;9:629-35.

- [18] Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol.* 2011;12:489-95.
- [19] Reisinger KW, Bosmans JW, Uittenbogaart M, Alsoumaili A, Poeze M, Sosef MN, et al. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery. *Ann Surg Oncol.* 2015.
- [20] Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, et al. Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. *PLoS One.* 2015;10:e0129742.
- [21] Alberda WJ, Verhoef C, Nuyttens JJ, van Meerten E, Rothbarth J, de Wilt JH, et al. Intraoperative radiation therapy reduces local recurrence rates in patients with microscopically involved circumferential resection margins after resection of locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys.* 2014;88:1032-40.
- [22] Ayez N, Alberda WJ, Burger JW, Eggermont AM, Nuyttens JJ, Dwarkasing RS, et al. Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary? *Ann Surg Oncol.* 2013;20:155-60.
- [23] de Bruin AF, Nuyttens JJ, Ferenschild FT, Planting AS, Verhoef C, de Wilt JH. Preoperative chemoradiation with capecitabine in locally advanced rectal cancer. *Neth J Med.* 2008;66:71-6.
- [24] Ferenschild FT, Vermaas M, Nuyttens JJ, Graveland WJ, Marinelli AW, van der Sijp JR, et al. Value of intraoperative radiotherapy in locally advanced rectal cancer. *Dis Colon Rectum.* 2006;49:1257-65.
- [25] Ayez N, Burger JW, van der Pool AE, Eggermont AM, Grunhagen DJ, de Wilt JH, et al. Long-term results of the "liver first" approach in patients with locally advanced rectal cancer and synchronous liver metastases. *Dis Colon Rectum.* 2013;56:281-7.
- [26] van der Pool AE, de Wilt JH, Lalmahomed ZS, Eggermont AM, Ijzermans JN, Verhoef C. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. *Br J Surg.* 2010;97:383-90.
- [27] Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. *PLoS medicine.* 2013;10:e1001453.
- [28] Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. *Annu Rev Med.* 2011;62:265-79.
- [29] Levolger S, van Vugt JL, de Bruin RW, JN IJ. Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies. *Br J Surg.* 2015.
- [30] Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell metabolism.* 2012;16:153-66.
- [31] Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. *Nature reviews Cancer.* 2014;14:754-62.
- [32] Norwegian University of Science and Technology, St. Olavs Hospital. Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy. 2015.
- [33] Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. *Cell.* 2010;142:531-43.
- [34] Jameson GS, Hoff DDV, Weiss GJ, Richards DA, Smith DA, Becerra C, et al. Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. *J Clin Oncol.* 2012;30 (Suppl).
- [35] Dingemans AM, de Vos-Geelen J, Langen R, Schols AM. Phase II drugs that are currently in development for the treatment of cachexia. *Expert Opin Investig Drugs.* 2014;23:1655-69.



**Table 1.** Baseline Demographic and Clinical characteristics of the 122 Patients Included in the Study

**Table 1. Baseline Demographic and Clinical Characteristics of the 122 Patients Included in the Study**

|   |                     | Number of patients      | Median (IQR)       |
|---|---------------------|-------------------------|--------------------|
| Age (years)                                       |                     |                         | 61 (53.0 – 66.3)   |
| Gender (M : F)                                    |                     | 71 : 51 (58.2% : 41.8%) |                    |
| Cardiac comorbidity (excluding hypertension)      |                     | 10 (8.2%)               |                    |
| Respiratory comorbidity                           |                     | 19 (15.6%)              |                    |
| Diabetes  |                     | 14 (11.5%)              |                    |
| BMI (kg/m <sup>2</sup> )*                         |                     |                         | 24.3 (22.0 – 26.8) |
| Tumor location (cm)*                              | < 6                 | 60 (49.6%)              |                    |
|   | ≥ 6                 | 61 (50.4%)              |                    |
| CEA (ng/mL)*                                      | < 5                 | 32 (43.2%)              |                    |
|   | ≥ 5                 | 42 (56.8%)              |                    |
| Clinical T-stage*                                 | T3                  | 65 (53.7%)              |                    |
|   | T4                  | 56 (46.3%)              |                    |
| Clinical N-stage*                                 | N-                  | 25 (20.7%)              |                    |
|   | N+                  | 96 (79.3%)              |                    |
| Clinical M-stage*                                 | M0                  | 82 (67.2%)              |                    |
|   | M1                  | 40 (32.8%)              |                    |
| Time interval between NACRT and resection (days)  |                     |                         | 70 (62.5 – 84.5)   |
| Pathologic T-stage*                               | ypT0                | 25 (20.7%)              |                    |
|   | ypT1                | 4 (3.3%)                |                    |
|   | ypT2                | 16 (13.2%)              |                    |
|   | ypT3                | 52 (43.0%)              |                    |
|   | ypT4                | 24 (19.8%)              |                    |
| Pathologic N-stage*                               | ypN0                | 84 (69.4%)              |                    |
|   | ypN1                | 25 (20.7%)              |                    |
|   | ypN2                | 12 (9.9%)               |                    |
| Pathologic M-stage                                | ypM0                | 83 (68.0%)              |                    |
|   | ypM1                | 39 (32.0%)              |                    |
| CRM   | R0                  | 100 (82.0%)             |                    |
|   | R1                  | 20 (16.4%)              |                    |
|   | R2                  | 2 (1.6%)                |                    |
| Vaso-invasion*                                    | No                  | 82 (83.7%)              |                    |
|   | Yes                 | 16 (16.3%)              |                    |
| Perineural growth*                                | No                  | 82 (83.7%)              |                    |
|   | Yes                 | 16 (16.3%)              |                    |
| Lymphoinvasion*                                   | No                  | 60 (95.2%)              |                    |
|   | Yes                 | 3 (4.8%)                |                    |
| Surgical procedure (all open procedures)          | LAR                 | 45 (36.9%)              |                    |
|   | APR                 | 45 (36.9%)              |                    |
|   | Pelvic exenteration | 32 (26.2%)              |                    |
| Intraoperative radiotherapy                       |                     | 16 (13.1%)              |                    |
| SMI pre-NACRT (cm <sup>2</sup> /m <sup>2</sup> )  |                     |                         | 46.6 (41.2 – 53.4) |
| SMI post-NACRT (cm <sup>2</sup> /m <sup>2</sup> ) |                     |                         | 46.9 (40.2 – 53.1) |

\*Data missing for some patients. M : F: Male : Female. BMI: Body-mass index. CEA: Carcinoembryonic antigen. SMI: Skeletal muscle index assessed at the third lumbar vertebrae, and standardized for patient height. NACRT: Neo-adjuvant chemoradiotherapy. CRM Circumferential resection margin, an R1 resection was defined as a circumferential resection margin < 2mm.



**Table 2.** Univariate and Multivariate Cox Regression Analysis for Disease-Free Survival

|                             |                       | Univariate analysis |              | Multivariable analysis |              |
|-----------------------------|-----------------------|---------------------|--------------|------------------------|--------------|
|                             |                       | Hazard Ratio        | <i>P</i>     | Hazard Ratio           | <i>P</i>     |
| Gender                      | Male                  | 1.00 (reference)    |              |                        |              |
|                             | Female                | 1.04 [0.59 – 1.81]  | 0.899        |                        |              |
| Age                         | Per year              | 0.98 [0.96 – 1.00]  | 0.089        |                        |              |
| Diabetes                    | No                    | 1.00 (reference)    |              |                        |              |
|                             | Yes                   | 0.52 [0.16 – 1.68]  | 0.278        |                        |              |
| Δ SMI                       | Per 1% change         | 0.96 [0.94 – 0.99]  | <b>0.004</b> | 0.97 [0.95 – 1.00]     | <b>0.025</b> |
| BMI                         | Per kg/m <sup>2</sup> | 1.04 [0.97 – 1.12]  | 0.238        |                        |              |
| Tumor location (cm)         | < 6                   | 1.00 (reference)    |              |                        |              |
|                             | ≥ 6                   | 0.85 [0.48 – 1.48]  | 0.557        |                        |              |
| CEA (ng/mL)                 | < 5                   | 1.00 (reference)    |              |                        |              |
|                             | ≥ 5                   | 1.56 [0.76 – 3.20]  | 0.223        |                        |              |
| Surgical procedure          | LAR                   | 1.00 (reference)    |              |                        |              |
|                             | APR                   | 1.38 [0.71 – 2.70]  | 0.342        |                        |              |
|                             | Pelvic exenteration   | 1.79 [0.87 – 3.67]  | 0.111        |                        |              |
| Intraoperative radiotherapy | No                    | 1.00 (reference)    |              |                        |              |
|                             | Yes                   | 2.11 [1.05 – 4.22]  | <b>0.035</b> | 1.44 [0.47 – 4.39]     | 0.523        |
| Pathologic T-stage          | ypT0 – ypT3           | 1.00 (reference)    |              |                        |              |
|                             | ypT4                  | 2.10 [1.13 – 3.89]  | <b>0.019</b> | 1.23 [0.56 – 2.71]     | 0.608        |
| Pathologic N-stage          | ypN0                  | 1.00 (reference)    |              |                        |              |
|                             | ypN1 or ypN2          | 2.44 [1.38 – 4.30]  | <b>0.002</b> | 1.85 [1.01 – 3.40]     | <b>0.047</b> |
| CRM                         | R0                    | 1.00 (reference)    |              |                        |              |
|                             | R1 or R2              | 2.19 [1.17 – 4.13]  | <b>0.015</b> | 1.04 [0.37 – 2.94]     | 0.944        |
| PCR                         | Yes                   | 1.00 (reference)    |              |                        |              |
|                             | No                    | 3.72 [1.34 – 10.35] | <b>0.012</b> | 2.75 [0.92 – 8.20]     | 0.069        |

BMI: Body-mass index. CEA: Carcinoembryonic antigen. SMI: Skeletal muscle index assessed at the third lumbar vertebrae, and standardized for patient height. NACRT: Neo-adjuvant chemoradiotherapy. CRM Circumferential resection margin. PCR Pathological complete response.

**Table 3.** Univariate and Multivariate Cox Regression Analysis for Distant Metastasis-Free Survival in


Patients without Evidence of Metastatic Disease at Presentation

|                     |                       | Univariate analysis |              | Multivariable analysis |              |
|---------------------|-----------------------|---------------------|--------------|------------------------|--------------|
|                     |                       | Hazard Ratio        | <i>P</i>     | Hazard Ratio           | <i>P</i>     |
| Gender              | Male                  | 1.00 (reference)    |              |                        |              |
|                     | Female                | 1.38 [0.58 – 3.27]  | 0.469        |                        |              |
| Age                 | Per year              | 0.98 [0.95 – 1.02]  | 0.274        |                        |              |
| Diabetes            | No                    | 1.00 (reference)    |              |                        |              |
|                     | Yes                   | 0.04 [0.00 – 21.38] | 0.319        |                        |              |
| Δ SMI               | Per 1% change         | 0.93 [0.88 – 0.98]  | <b>0.007</b> | 0.94 [0.90 – 0.99]     | <b>0.013</b> |
| BMI                 | Per kg/m <sup>2</sup> | 1.10 [0.99 – 1.22]  | 0.084        |                        |              |
| Tumor location (cm) | < 6                   | 1.00 (reference)    |              |                        |              |
|                     | ≥ 6                   | 0.42 [0.16 – 1.09]  | 0.073        |                        |              |
| CEA (ng/mL)         | < 5                   | 1.00 (reference)    |              |                        |              |
|                     | ≥ 5                   | 1.31 [0.42 – 4.10]  | 0.638        |                        |              |
| Surgical procedure  | LAR                   | 1.00 (reference)    |              |                        |              |


|                             |                     |                        |              |                    |              |
|-----------------------------|---------------------|------------------------|--------------|--------------------|--------------|
|                             | APR                 | 1.80 [0.60 – 5.37]     | 0.294        |                    |              |
|                             | Pelvic exenteration | 2.09 [0.66 – 6.60]     | 0.209        |                    |              |
| Intraoperative radiotherapy | No                  | 1.00 (reference)       |              |                    |              |
|                             | Yes                 | 2.61 [0.96 – 7.14]     | 0.061        |                    |              |
| Pathologic T-stage          | ypT0 – ypT3         | 1.00 (reference)       |              |                    |              |
|                             | ypT4                | 1.90 [0.73 – 4.89]     | 0.186        |                    |              |
| Pathologic N-stage          | ypN0                | 1.00 (reference)       |              |                    |              |
|                             | ypN1 or ypN2        | 3.68 [1.56 – 8.69]     | <b>0.003</b> | 3.49 [1.46 – 8.35] | <b>0.005</b> |
| CRM                         | R0                  | 1.00 (reference)       |              |                    |              |
|                             | R1 or R2            | 2.32 [0.90 – 5.98]     | 0.082        |                    |              |
| PCR                         | Yes                 | 1.00 (reference)       |              |                    |              |
|                             | No                  | 29.94 [0.37 – 2424.34] | 0.129        |                    |              |

BMI: Body-mass index. CEA: Carcinoembryonic antigen. SMI: Skeletal muscle index assessed at the third lumbar vertebrae, and standardized for patient height. NACRT: Neo-adjuvant chemoradiotherapy. CRM Circumferential resection margin. PCR Pathological complete response.

**Figure 1.** Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy does not affect overall survival in rectal patients following surgical resection (log rank test  $p = 0.520$ ).



**Figure 2.** Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy is associated with impaired disease-free survival in rectal cancer patients following surgical resection (log-rank  $p = 0.027$ ).



**Figure 3.** Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy is associated with the development of distant metastases following curative intent treatment in patients without evidence of metastatic disease at presentation (log-rank  $p = 0.009$ ).

